Gadopiclenol
Paramagnetic Contrast Media
Sold as Vueway · Elucirem
- Drug class
- Paramagnetic Contrast Media
- Availability
- Prescription only
- Routes
- Intravenous
- Markets covered
- 4
- Products on record
- 8
- FDA reports (12 mo)
- 90
Overview
Gadopiclenol is an active pharmaceutical ingredient in the Paramagnetic Contrast Media group (V08CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | May 22, 2026 |
| EU European Union | EMA | 2 | March 12, 2026 |
| US United States | FDA | 1 | April 3, 2026 |
| CA Canada | Health Canada | 1 | May 8, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
This medicinal product is for diagnostic use only. Elucirem is indicated in adults and children aged 2 years and older for contrast- enhanced magnetic resonance imaging (MRI) to improve detection and visualization of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of: - the brain, spine, and associated tissues of the central nervous system (CNS); - the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
It should be used only when diagnostic information is essential and not available with unenhanced MRI.
How to take
EUEuropean Union· EMA
2 products
Uses
This medicinal product is for diagnostic use only. Elucirem is indicated in adults and children from birth for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualization of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of: - the brain, spine, and associated tissues of the central nervous system (CNS); - the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
It should be used only when diagnostic information is essential and not available with unenhanced MRI.
How to take
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Vueway ® is indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) Vueway is a gadolinium-based contrast agent indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) ( 1 )
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [4].
Brands in Canada (1)
Sources & citations
- [1]MHRA (UK) · PLGB123080034 · revised April 17, 2026
- [2]European Medicines Agency · EMEA/H/C/005626 · revised March 12, 2026
- [3]FDA DailyMed · 192725e9-e83e-1a… · revised April 3, 2026 [PDF]
- [4]Health Canada (DPD) · 02567334 · revised May 8, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.